These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 8126248)

  • 121. Iron status of dialysis patients under rhuEPO therapy.
    Hörl WH; Dreyling K; Steinhauer HB; Engelhardt R; Schollmeyer P
    Contrib Nephrol; 1990; 87():78-86. PubMed ID: 2093543
    [No Abstract]   [Full Text] [Related]  

  • 122. 'Blood will have blood'.
    Mandell BF
    Cleve Clin J Med; 2008 May; 75(5):327. PubMed ID: 18556873
    [No Abstract]   [Full Text] [Related]  

  • 123. Haptoglobin 2-2 phenotype is associated with decreased serum iron levels in endstage renal disease patients resistant to rhEPO therapy.
    Martins F; Catarino C; Rocha-Pereira P; Reis F; Sameiro-Faria M; Miranda V; Belo L; Bronze-da-Rocha E; Costa E; Santos-Silva A
    Br J Biomed Sci; 2014; 71(2):79-81. PubMed ID: 24974683
    [No Abstract]   [Full Text] [Related]  

  • 124. Iron and erythropoiesis in normal subjects and in pregnancy.
    Cavill I
    J Perinat Med; 1995; 23(1-2):47-50. PubMed ID: 7658319
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Recombinant human erythropoietin: duplicate publication.
    Warady BA
    Pediatr Nephrol; 1991 Nov; 5(6):763. PubMed ID: 1768593
    [No Abstract]   [Full Text] [Related]  

  • 126. Efficacy of erythropoietin as a neuroprotective agent in CKD-associated cognitive dysfunction: A literature systematic review.
    Barbieri M; Chiodini P; Di Gennaro P; Hafez G; Liabeuf S; Malyszko J; Mani LY; Mattace-Raso F; Pepin M; Perico N; Simeoni M; Zoccali C; Tortorella G; Capuano A; Remuzzi G; Capasso G; Paolisso G;
    Pharmacol Res; 2024 May; 203():107146. PubMed ID: 38493928
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Changes in red blood cell volume under recombinant human erythropoietin therapy.
    Schmidt R; Lerche D; Dörp E; Winkler R; Klinkmann H
    Contrib Nephrol; 1990; 87():52-8. PubMed ID: 2093541
    [No Abstract]   [Full Text] [Related]  

  • 128. Anemia after renal transplantation.
    Afzali B; Al-Khoury S; Shah N; Mikhail A; Covic A; Goldsmith D
    Am J Kidney Dis; 2006 Oct; 48(4):519-36. PubMed ID: 16997048
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Erythropoietin-induced hypertensive urgency in a patient with chronic renal insufficiency: case report and review of the literature.
    Novak BL; Force RW; Mumford BT; Solbrig RM
    Pharmacotherapy; 2003 Feb; 23(2):265-9. PubMed ID: 12587817
    [TBL] [Abstract][Full Text] [Related]  

  • 130. Recombinant human erythropoietin treatment in chronic renal failure: effects on hemostasis and vasculature.
    Cases A
    Drugs Today (Barc); 2000 Aug; 36(8):541-56. PubMed ID: 12847580
    [TBL] [Abstract][Full Text] [Related]  

  • 131. Effects of recombinant human erythropoietin on the haemopoietic bone marrow monitored by magnetic resonance spectroscopy in patients with end-stage renal disease.
    Jensen KE; Stenver D; Jensen M; Grundtvig P; Thomsen C; Karle H; Henriksen O; Nielsen B
    Magn Reson Imaging; 1990; 8(3):237-43. PubMed ID: 2366637
    [TBL] [Abstract][Full Text] [Related]  

  • 132. Clinical use of growth factors in chronic renal failure.
    Vijayan A; Behrend T; Miller SB
    Curr Opin Nephrol Hypertens; 2000 Jan; 9(1):5-10. PubMed ID: 10654818
    [TBL] [Abstract][Full Text] [Related]  

  • 133. Diagnosis and management of iron deficiency in chronic dialysis patients.
    van Zyl-Smit R
    Curr Opin Nephrol Hypertens; 2000 Nov; 9(6):669-74. PubMed ID: 11128430
    [TBL] [Abstract][Full Text] [Related]  

  • 134. Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients.
    Evans SJ
    Nephron; 1997; 76(1):116; author reply 117. PubMed ID: 9171310
    [No Abstract]   [Full Text] [Related]  

  • 135. Diagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): is too little iron making your patient sick?
    Fertrin KY
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):478-486. PubMed ID: 33275757
    [TBL] [Abstract][Full Text] [Related]  

  • 136. Anemia in heart failure: still an unsolved enigma.
    Sharma YP; Kaur N; Kasinadhuni G; Batta A; Chhabra P; Verma S; Panda P
    Egypt Heart J; 2021 Aug; 73(1):75. PubMed ID: 34453627
    [TBL] [Abstract][Full Text] [Related]  

  • 137. Mechanism by which rHuEPO improves submaximal exercise performance.
    Noakes TD
    Eur J Appl Physiol; 2008 Jul; 103(4):485. PubMed ID: 18368420
    [No Abstract]   [Full Text] [Related]  

  • 138. Resistance of dialyzed patients to erythropoietin.
    Alves MT; Vilaça SS; Carvalho Md; Fernandes AP; Dusse LM; Gomes KB
    Rev Bras Hematol Hemoter; 2015; 37(3):190-7. PubMed ID: 26041422
    [TBL] [Abstract][Full Text] [Related]  

  • 139. Elevated glycosylated hemoglobin in a patient receiving recombinant erythropoietin.
    Schwartz ID; Warady BA; Reddig N; Meek K
    Pediatr Nephrol; 1996 Dec; 10(6):809-10. PubMed ID: 8971913
    [No Abstract]   [Full Text] [Related]  

  • 140. Partially thrombosed aneurysm of the abdominal aorta: Unusual cause of chronic inflammation and resistance to recombinant human erythropoietin.
    El Amrani M; El Kharras A; Asserraji M
    Indian J Nephrol; 2014 Jan; 24(1):38-40. PubMed ID: 24574630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.